Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ACETASOL HC vs ALFENTANIL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.
Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Treatment of superficial bacterial infections of the external auditory canal (swimmer's ear),Treatment of fungal infections of the external ear
Analgesic adjunct during general anesthesia,Induction of anesthesia,Maintenance of anesthesia for short surgical procedures,Off-label: Procedural sedation in monitored settings
5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.
Hydrocortisone has a terminal elimination half-life of approximately 1.5-2 hours. Acetic acid has a half-life of minutes due to rapid metabolism. Clinical context: dosing interval is typically 3-4 times daily for otic use.
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours). Clinically, context-sensitive half-time is short (~40 min after 3-hour infusion) due to rapid redistribution and metabolism.
Not extensively metabolized; undergoes minimal hepatic metabolism.
Alfentanil is primarily metabolized by hepatic cytochrome P450 enzymes, mainly CYP3A4, through oxidative N-dealkylation and O-demethylation to inactive metabolites.
Acetasol HC is a combination product containing hydrocortisone and acetic acid. Hydrocortisone is primarily metabolized in the liver and excreted renally as inactive metabolites; less than 1% is excreted unchanged. Acetic acid is rapidly metabolized via the tricarboxylic acid cycle and eliminated as carbon dioxide and water. Biliary/fecal elimination is negligible for both components.
Primarily hepatic metabolism via CYP3A4; <1% excreted unchanged in urine; metabolites (mainly noralfentanil) excreted renally. Biliary/fecal excretion of metabolites accounts for ~30%.
Hydrocortisone is approximately 90-95% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid has negligible protein binding (<10%).
~92% bound primarily to alpha-1-acid glycoprotein (AAG) and albumin.
Hydrocortisone Vd is approximately 0.3-0.5 L/kg, indicating distribution into total body water. Acetic acid Vd is approximately 0.4 L/kg. Clinical meaning: limited tissue distribution; primarily remains in extracellular fluid.
Vd: 0.4–1.0 L/kg (mean ~0.75 L/kg). Moderate Vd reflecting rapid distribution to tissues, especially brain and muscle.
Otic: Bioavailability is approximately 10-20% via the ear canal due to slow permeation through tympanic membrane; systemic absorption is minimal (<10% of applied dose). Oral: Not applicable; product is for otic use only.
IV: 100%. IM: ~90%. Epidural: ~30–50% due to local uptake and redistribution. No significant oral bioavailability.
No renal adjustment required as systemic absorption is negligible.
GFR 10-50 m L/min: administer with caution, consider dose reduction of 25-50%; GFR <10 m L/min: reduce dose by 50% and extend dosing interval.
No hepatic adjustment required as systemic absorption is negligible.
Child-Pugh class A: no adjustment needed; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: reduce dose by 75%.
Same as adult: 5 drops into affected ear(s) 3-4 times daily. Safety and efficacy in children under 2 years not established.
Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-2 mcg/kg/min. For neonates, reduce dose by 30-50% due to immature clearance.
No specific adjustment; use same adult dosing. Consider age-related skin thinning and potential for increased systemic absorption in cases of tympanic membrane perforation.
Reduce initial IV bolus by 30-50% to 3-10 mcg/kg; titrate carefully; monitor for prolonged sedation and respiratory depression.
None
Risk of respiratory depression: Alfentanil can cause severe, life-threatening, or fatal respiratory depression. Monitor for respiratory depression, especially during initiation or following dose increases. Accidental ingestion of even one dose can be fatal. Concomitant use with central nervous system depressants (e.g., benzodiazepines, alcohol) may increase risk. Alfentanil is an opioid agonist and a Schedule II controlled substance with high potential for abuse and addiction.
For otic use only; not for ophthalmic use,Prolonged use may result in overgrowth of non-susceptible organisms,Discontinue if sensitization or irritation occurs,Caution in patients with perforated tympanic membrane
Respiratory depression: Potentially fatal; monitor oxygenation and ventilation.,Abuse potential: Schedule II controlled substance; risk of addiction, abuse, and diversion.,Concomitant use with CNS depressants: Increases risk of profound sedation, respiratory depression, coma, and death; limit use or monitor closely.,Geriatric and cachectic patients: Increased sensitivity; reduce initial dose.,Hepatic impairment: Alfentanil clearance is reduced in patients with cirrhosis; consider dose adjustment.,Bradycardia and hypotension: Use with caution in patients with hypovolemia or reduced cardiac reserve.,Serotonin syndrome: Risk with concurrent serotonergic drugs (e.g., MAOIs, SSRIs, triptans); monitor for symptoms.,Withdrawal: Prolonged use may lead to physical dependence; taper dose gradually.
Hypersensitivity to any component,Perforated tympanic membrane,Viral or fungal infections of the ear (except when used for fungal infections as indicated)
Hypersensitivity to alfentanil, fentanyl, or any opioid,Significant respiratory depression (e.g., acute asthma, COPD in acute exacerbation),Acute or severe bronchial asthma,Suspected or known paralytic ileus,MAO inhibitor use within 14 days (serotonin syndrome risk),Myasthenia gravis (relative contraindication due to risk of respiratory muscle weakness),Morbid obesity with sleep apnea (relative contraindication; increased risk of respiratory depression)
No known food interactions. Avoid excessive alcohol as it may impair immune response.
No significant food interactions known. Avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 metabolism, potentially prolonging effects.
ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies in pregnant women. Animal reproduction studies with topical glucocorticoids have shown an increased risk of cleft palate and other malformations at high doses. Based on limited human data and low systemic exposure, use during pregnancy is generally considered low risk. However, as a precaution, avoid use in the first trimester unless clearly needed.
Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid prolonged use or high doses near term; use during labor may cause respiratory depression in neonate.
Systemic absorption after otic application is minimal. It is not known whether hydrocortisone or acetic acid is excreted in human milk. M/P ratio is not available. Concentrations in milk are likely negligible. Use is considered compatible with breastfeeding.
Alfentanil is excreted into breast milk in very low concentrations; estimated relative infant dose is low (<2% of maternal weight-adjusted dose). M/P ratio not determined in humans. Compatible with breastfeeding with caution; monitor infant for drowsiness, feeding difficulties.
No dose adjustment is necessary in pregnancy due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety of this topical otic preparation.
Pregnancy can alter alfentanil pharmacokinetics: increased volume of distribution, decreased plasma clearance, prolonged elimination half-life. Dose reduction may be needed for prolonged use; titrate to effect. During labor, use smallest effective dose.
ACETASOL HC (acetic acid 2%, hydrocortisone 1%) is used for otitis externa. Acetic acid restores acidic p H of ear canal, inhibiting bacterial and fungal growth. Hydrocortisone reduces inflammation and pruritus. Ensure tympanic membrane is intact before use due to risk of ototoxicity with corticosteroids in middle ear. Do not use for more than 7 days. Shake well before instillation.
Alfentanil is a potent, short-acting synthetic opioid (4-5 times more potent than fentanyl) with rapid onset (1-2 min) and brief duration (5-10 min). Primarily used for induction and maintenance of anesthesia, especially in short procedures. Requires careful monitoring of respiratory depression and chest wall rigidity, particularly during rapid IV administration. Hepatic metabolism (CYP3A4) affected by liver disease; reduce dose. Decrease dose in elderly and hypovolemic patients. Not recommended for chronic pain due to short half-life.
Instill 3-4 drops into affected ear every 2-3 hours for 5-7 days.,Lie on side for 5 minutes after instillation to ensure coverage.,Avoid inserting cotton swabs or objects into the ear.,Discontinue if pain, worsening discharge, or rash occurs.,Do not use if ear drum is perforated or if you have a history of ear surgery.
This medication causes drowsiness and dizziness; avoid driving or operating machinery for at least 24 hours after administration.,Report any difficulty breathing, chest tightness, or feeling faint immediately.,Alfentanil is used only in hospital settings under direct supervision of healthcare professionals.,Inform your doctor if you have a history of liver disease, lung disease, or drug/alcohol abuse.,Do not consume alcohol or other sedatives while under the effects of alfentanil.
No interactions on record
"Propantheline, an anticholinergic agent, can competitively antagonize muscarinic acetylcholine receptors, potentially reducing gastrointestinal motility and secretion. Alfentanil, a mu-opioid receptor agonist, also decreases gastrointestinal motility through central and peripheral opioid receptors. Concomitant use may synergistically inhibit peristalsis, leading to severe constipation, paralytic ileus, or delayed gastric emptying, which can increase the risk of aspiration and complicate anesthesia recovery."
"Alfentanil, a potent opioid analgesic, can cause significant hypotension and respiratory depression. When combined with furosemide, a loop diuretic that reduces blood volume and vascular resistance, there is a synergistic decrease in blood pressure, which may precipitate cardiovascular collapse, especially in patients with compromised circulatory reserves. Additionally, furosemide may enhance the sedative and respiratory depressant effects of alfentanil, leading to increased risk of respiratory acidosis and altered mental status."
"Alfentanil, a potent mu-opioid receptor agonist, can enhance the bradycardic effects of nebivolol, a beta-1 selective blocker with additional nitric oxide-mediated vasodilation. The combination may lead to excessive slowing of heart rate, reduced cardiac output, and potential hemodynamic instability, particularly in patients with underlying cardiac conduction abnormalities or hypovolemia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ACETASOL HC vs ALFENTANIL, answered by our medical review team.
ACETASOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.. ALFENTANIL is a Opioid Analgesic that works by Alfentanil is a potent, short-acting synthetic opioid analgesic that primarily acts as a mu-opioid receptor agonist. It binds to mu-opioid receptors in the central nervous system, leading to G-protein coupled activation of inwardly rectifying potassium channels and inhibition of voltage-gated calcium channels, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ACETASOL HC and ALFENTANIL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ACETASOL HC is: 5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.. The standard adult dose of ALFENTANIL is: Initial IV bolus of 5-20 mcg/kg; maintenance infusion of 0.5-1.5 mcg/kg/min; incremental boluses of 5-10 mcg/kg as needed. Induction of anesthesia: 50-100 mcg/kg IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ACETASOL HC and ALFENTANIL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ACETASOL HC is classified as Category C. ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies i. ALFENTANIL is classified as Category C. Alfentanil is an opioid analgesic; limited human data. No clear evidence of major malformations, but third trimester use may cause neonatal opioid withdrawal syndrome (NOWS). Avoid. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.